{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"46","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"description":"Event-free survival: Time to recurrence, second malignancy, or death as a first event, estimated from a Kaplan Meier curve","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with parameningeal (without intracranial extension) and paraspinal tumors should receive chemotherapy beginning Week 1 and begin radiation therapy at Week 20. Weeks 1-6 vincristine sulfate (VCR) \\& irinotecan hydrochloride (IRIN), Weeks 7-34 vincristine sulfate (VCR), Cyclophosphamide (CPM) with MESNA, Doxorubicin hydrochloride (DOX), Etoposide (ETOP), Ifosfamide (IFOS) with MESNA. Weeks 35-54 vincristine sulfate (VCR), Dactinomycin (DACT) and Cyclophosphamide (CPM) with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.","id":"OG000","title":"High_Risk_Rhabdomyosarcoma"}],"paramType":"NUMBER","populationDescription":"All eligible patients","reportingStatus":"POSTED","timeFrame":"4 years","title":"Percentage of Patients Event Free at 4 Years Following Study Entry","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}